Your browser doesn't support javascript.
loading
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors.
Su, Pan; Xiao, Liuling; Ye, Lingqun; Wang, Zhuo; Xiong, Wei; Wang, Qiang; Ma, Xingzhe; Xian, Miao; Yang, Maojie; Zu, Youli; Pingali, Sai Ravi; Qian, Jianfei; Yi, Qing.
Afiliação
  • Su P; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Xiao L; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Ye L; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Wang Z; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Xiong W; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Wang Q; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Ma X; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Xian M; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Yang M; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Zu Y; Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA.
  • Pingali SR; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
  • Qian J; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA.
  • Yi Q; Center for Translational Research in Hematological Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston, TX, USA. QYi@houstonmethodist.org.
J Hematol Oncol ; 15(1): 55, 2022 05 07.
Article em En | MEDLINE | ID: mdl-35526043
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Inibidores de Proteassoma / Mieloma Múltiplo Limite: Humans Idioma: En Revista: J Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Inibidores de Proteassoma / Mieloma Múltiplo Limite: Humans Idioma: En Revista: J Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article